MedTrace Logo

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

NCT02136511 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2014-10-28

No results posted yet for this study

Summary

This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.

Conditions

  • Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

Idelalisib

Idelalisib 150 mg tablet administered orally twice daily

DRUG

Rituximab

Rituximab administered intravenously starting at 375 mg/m\^2 at Week 0 and continuing with a dose of 500 mg/m\^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.

Sponsors & Collaborators

Principal Investigators

  • Thomas Jahn, MD · Gilead Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Ireland
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02136511 on ClinicalTrials.gov